Clinical trials: Influenza Viruses
Influenza
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
The study will evaluate the safety and immunogenicity of the 2014-2015 formulation of Fluzone Quadrivalent vaccine, administered in a 1- or 2-dose schedule, in accordance with the Advisory Committee on Immunization Practices…
- Trial name
- NCT02222870
- Testing
- Fluzone® Quadrivalent Influenza Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
The purpose of this study is to demonstrate the efficacy of an investigational Vero cell-derived, trivalent, seasonal influenza vaccine to prevent infection with an influenza virus that is antigenically similar to one of the…
- Trial name
- NCT00800605
- Testing
- Vero cell-derived, trivalent, seasonal influenza vaccine
- Where
- 36 sites in United States
- Volunteers
- 7,250 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Flu, Cold
Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal
The common cold is a major cause of nasal obstruction and reaches children and adults two or more times a year. At the moment, there is no cure for the common cold, and therefore the reduction of symptoms is the focus of the…
- Conditions
- Flu, Cold, Allergic Disorder of Respiratory System
- Trial name
- NCT01533220
- Testing
- naphazoline hydrocloride, Naphazoline hydrocloride + Pheniramine Maleate + Panthenol
- Volunteers
- 132 people
- Sponsor
- EMS
Acute Respiratory Tract Infection, Flu, Human
Effectiveness of a Nasal Spray on Viral Respiratory Infections
There is no cure for cold or flu, most people recover in about within two weeks. Paracetamol may be used to reduce aches or treat fever, headache, or body aches.
- Conditions
- Acute Respiratory Tract Infection, Flu, Human, COVID-19, Common Cold
- Trial name
- NCT06278324
- Testing
- Nasal Spray HSV Treatment
- Where
- France
- Volunteers
- 76 people
- Sponsor
- CEN Biotech
Seasonal Influenza
Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010
This is a trial for annual registration of the updated seasonal influenza vaccine formulation.
- Trial name
- NCT00956761
- Testing
- Seasonal Influenza Vaccine (MF59C.1)
- Where
- 2 sites in Italy
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis
Respiratory Infection Virus, COVID-19
Noseguard for Prevention of Respiratory Infections in Real-World Use
This study is a prospective clinical study to evaluate the effectiveness of combined use of two nasal protective medical devices (Noseguard and Noseguard Night) in reducing respiratory infection rates, including COVID-19 and…
- Conditions
- Respiratory Infection Virus, COVID-19, Influenza
- Trial name
- NCT07516977
- Testing
- Noseguard and Noseguard Night
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Influenza A
Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers
The primary objective is to determine the dose level of live, wild-type A/California/ H1N1 2009 virus that has an appropriate safety and illness/infectivity profile to be used as an influenza virus, challenge strain in future…
- Trial name
- NCT02014870
- Testing
- 1:1000 Live wild-type A/California/H1N1 2009, 1:100 Live wild-type A/California/H1N1 2009, 1:10 Live wild-type A/California/H1N1 2009
- Where
- Belgium
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Immune Targeting Systems Ltd
Influenza
Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers
The purpose of this study is to determine the efficacy of the liquid formulation of CAIVT against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months, attending day care centers…
- Trial name
- NCT00192283
- Testing
- CAIV-T
- Where
- Finland
- Volunteers
- 2,903 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Common Cold/Flu, Nasal Congestion
Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults
Phase III clinical trial to evaluate the efficacy and safety of a fixed-dose combination of 1000 mg dipyrone monohydrate + 60 mg caffeine + 4 mg chlorpheniramine maleate in improving symptoms of the common cold and flu in adults.
- Conditions
- Common Cold/Flu, Nasal Congestion, Nasal Obstruction
- Trial name
- PANAMA (NCT07626437)
- Testing
- dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg, dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg
- Where
- 15 sites in Brazil
- Volunteers
- 620 people
- Sponsor
- Brainfarma Industria Química e Farmacêutica S/A
Respiratory Syncytial Virus
Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age
The purpose of this study is to assess the safety and immunogenicity of RSVpreF when coadministered with SIIV compared to sequential administration of the vaccines when given 1 month apart (SIIV followed by RSVpreF).
- Trial name
- NCT05301322
- Testing
- RSVpreF Vaccine, Seasonal Inactivated Influenza Vaccine
- Where
- 33 sites in Australia
- Volunteers
- 1,471 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Intracutaneous Delivery of Varied Dose Volumes of Saline
This study will evaluate intracutaneous delivery of 0.1, 0.25 and 0.5 milliliter volumes of saline from the FLUGEN 101.2 investigational microneedle-based device.
- Trial name
- NCT01767337
- Testing
- FLUGEN 101.2 device
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Influenza
Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses
The purpose of this study is to assess in healthy subjects the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses of CR8020, a monoclonal antibody against influenza A viruses.
- Trial name
- NCT01756950
- Testing
- 2 mg/kg CR8020, 5 mg/kg CR8020, 15 mg/kg CR8020
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza
Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation
This study is in support of the annual application for the variation of the vaccine strains for a marketing authorization. Objectives: To evaluate the compliance, in terms of immunogenicity, of the influenza vaccine (split…
- Trial name
- NCT00946179
- Testing
- Influenza virus (split virion, inactivated) vaccine
- Where
- 2 sites in Switzerland
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, Influenza A
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
This study is designed as a prospective, multicentric, sample collection study. The collected samples will be used for diagnostic research, product development and validation of the Panbio™ COVID-19/ Flu A\&B Rapid Panel for the…
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Trial name
- NCT05354115
- Testing
- Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel
- Where
- United States
- Volunteers
- 676 people
- Sponsor
- Abbott Rapid Dx
Influenza, Flu
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
The aim of the study was to describe the safety and immunogenicity of the 2017-2018 formulation of Fluzone Quadrivalent vaccine in children 6 months to < 9 years of age, and in adults 18 to < 65 years of age, and to describe the…
- Trial name
- NCT03308825
- Testing
- Fluzone Quadrivalent vaccine, Fluzone High-Dose vaccine
- Where
- 3 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Cough, Sore Throat
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza
A Phase 3, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of peramivir administered intravenously in addition to standard of care compared to standard of care alone in adults and…
- Conditions
- Cough, Sore Throat, Nasal Congestion, Headache
- Trial name
- NCT00958776
- Testing
- Peramivir+SOC
- Where
- 196 sites in United States, Argentina and 21 more
- Volunteers
- 405 people
- Sponsor
- BioCryst Pharmaceuticals
Healthy Volunteers
Annual Study to Investigate Inactivated Subunit Influenza Vaccine for the 2006/2007 Influenza Season in Europe.
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT00346723
- Testing
- Influvac® subunit influenza vaccine for i.m./deep s.c.injection
- Where
- Belgium
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Healthy
A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001
DNA vaccines consist of small pieces of DNA also known as plasmids, and have several potential advantages over traditional vaccines. Thus far, DNA vaccines appear to be well tolerated in humans.
- Trial name
- NCT01403155
- Testing
- INO-3401 + EP
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Influenza
Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958
The purpose of this study is to test the safety and tolerability of an investigational multi-dose inhaled flu medication, CS-8958. Study participants will include 16 males and females, aged 18-55 years of age, inclusive.
- Trial name
- NCT00995826
- Testing
- CS-8958
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Biota Scientific Management Pty Ltd
Influenza
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects
Annual trial for registration influenza vaccine with the strain composition for season 2008/2009
- Trial name
- NCT00748150
- Testing
- Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
- Where
- United Kingdom
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.